Hims & Hers Health (NYSE:HIMS) Rating Lowered to Hold at Wall Street Zen

Hims & Hers Health (NYSE:HIMS) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Monday.

HIMS has been the topic of a number of other research reports. Piper Sandler restated a “neutral” rating and set a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Morgan Stanley restated an “equal weight” rating and set a $40.00 price target on shares of Hims & Hers Health in a report on Wednesday, June 11th. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a report on Monday, June 23rd. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Finally, Truist Financial boosted their price target on shares of Hims & Hers Health from $45.00 to $48.00 and gave the company a “hold” rating in a report on Thursday, July 17th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus price target of $39.83.

Hims & Hers Health Price Performance

NYSE HIMS opened at $60.29 on Monday. The company’s 50 day simple moving average is $53.06 and its 200 day simple moving average is $43.35. Hims & Hers Health has a 12 month low of $13.47 and a 12 month high of $72.98. The company has a market capitalization of $13.50 billion, a P/E ratio of 87.38, a PEG ratio of 2.16 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The business had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same period in the previous year, the firm earned $0.05 EPS. The business’s revenue for the quarter was up 110.7% on a year-over-year basis. On average, analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,100 shares of the business’s stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $57.52, for a total value of $120,792.00. Following the completion of the sale, the insider directly owned 278,654 shares of the company’s stock, valued at $16,028,178.08. The trade was a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Soleil Boughton sold 2,572 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $58.70, for a total transaction of $150,976.40. Following the completion of the sale, the insider directly owned 155,593 shares of the company’s stock, valued at $9,133,309.10. This represents a 1.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 737,704 shares of company stock valued at $40,644,035. 17.71% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently bought and sold shares of HIMS. Smartleaf Asset Management LLC raised its stake in shares of Hims & Hers Health by 15.7% in the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock valued at $49,000 after buying an additional 227 shares in the last quarter. True Vision MN LLC raised its stake in shares of Hims & Hers Health by 3.6% in the 2nd quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock valued at $467,000 after buying an additional 328 shares in the last quarter. Allworth Financial LP raised its stake in shares of Hims & Hers Health by 20.0% in the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock valued at $56,000 after buying an additional 334 shares in the last quarter. Signaturefd LLC raised its stake in shares of Hims & Hers Health by 17.7% in the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock valued at $76,000 after buying an additional 388 shares in the last quarter. Finally, WealthPlan Investment Management LLC raised its stake in shares of Hims & Hers Health by 2.6% in the 2nd quarter. WealthPlan Investment Management LLC now owns 16,404 shares of the company’s stock valued at $818,000 after buying an additional 410 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.